A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies Article

Full Text via DOI: 10.1016/j.annonc.2020.08.639 Web of Science: 000573469100523
International Collaboration

Cited authors

  • Ku, G.; Bendell, J. C.; Tolcher, A. W.; Hurvitz, S. A.; Krishnamurthy, A.; El-Khoueiry, A. B.; Patnaik, A.; Shroff, R. T.; Noonan, A.; Hahn, N. M.; Matrana, M.; Zettl, M.; Aviano, K.; Mar, L.; Jolicoeur, P.; Olwill, S.; Bruns, I.; Piha-Paul, S.

Publication date

  • 2020

Published in

International Standard Serial Number (ISSN)

  • 0923-7534

Start page

  • S462

End page

  • S463


  • 31